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Inﬂammation in Alzheimer’s disease (AD) patients is character-
ized by increased cytokines and activated microglia. Epidemi-
ological studies suggest reduced AD risk associates with long-
term use of nonsteroidal anti-inﬂammatory drugs (NSAIDs).
Whereas chronic ibuprofen suppressed inﬂammation and
plaque-related pathology in an Alzheimer transgenic APPSw
mouse model (Tg2576), excessive use of NSAIDs targeting
cyclooxygenase I can cause gastrointestinal, liver, and renal
toxicity. One alternative NSAID is curcumin, derived from the
curry spice turmeric. Curcumin has an extensive history as a
food additive and herbal medicine in India and is also a potent
polyphenolic antioxidant. To evaluate whether it could affect
Alzheimer-like pathology in the APPSw mice, we tested a low
(160 ppm) and a high dose of dietary curcumin (5000 ppm) on
inﬂammation, oxidative damage, and plaque pathology. Low
and high doses of curcumin signiﬁcantly lowered oxidized pro-
teins and interleukin-1, a proinﬂammatory cytokine elevated in
the brains of these mice. With low-dose but not high-dose
curcumin treatment, the astrocytic marker GFAP was reduced,
and insoluble -amyloid (A), soluble A, and plaque burden
were signiﬁcantly decreased by 43–50%. However, levels of
amyloid precursor (APP) in the membrane fraction were not
reduced. Microgliosis was also suppressed in neuronal layers
but not adjacent to plaques. In view of its efﬁcacy and apparent
low toxicity, this Indian spice component shows promise for the
prevention of Alzheimer’s disease.
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Alzheimer’s disease (AD) involves a chronic CNS inﬂammatory
response that is associated with both head injury and -amyloid
(A) pathology (Rogers et al., 1996). In populations with pro-
longed use of nonsteroidal anti-inﬂammatory drugs (NSAIDs),
including the common over-the-counter medication ibuprofen,
the risk for AD is signiﬁcantly reduced (Breitner et al., 1995;
Stewart et al., 1997). Consistent with this epidemiological associ-
ation, chronic ibuprofen treatment signiﬁcantly suppressed in-
ﬂammation and the development of -amyloid pathology in an
animal model for Alzheimer’s disease, the Tg2576 APPSw trans-
genic mouse (Lim et al., 2000). However, a principal limitation
precluding widespread NSAID use for prevention of AD is
gastrointestinal and occasional liver and kidney toxicity caused by
inhibiting cyclooxygenase I (Bjorkman, 1998; Tomoda et al.,
1998; Cappell and Schein, 2000; McGettigan and Henry, 2000;
Sung et al., 2000). Side effect issues could be overcome using
alternative anti-inﬂammatory drugs directed against different in-
ﬂammatory targets.
Signiﬁcant oxidative damage occurs in AD (Smith et al., 1991;
Friedlich and Butcher, 1994; Smith et al., 1997; Montine et al.,
1999). Because antioxidants can protect neurons from -amyloid
toxicity in vitro (Behl et al., 1994; Mattson and Goodman, 1995),
a clinical trial was performed to test the ability of vitamin E to
slow down the progression of AD (Sano et al., 1997). However,
the limited success of this high-dose -tocopherol trial has gen-
erated interest in other antioxidants because -tocopherol (unlike
-tocopherol) is a poor scavenger of the nitric oxide (NO)-based
free radicals produced during inﬂammation (Christen et al.,
1997) and elevated in AD (Adams et al., 1991; Smith et al., 1997).
One phenolic antioxidant alternative is curcumin, a yellow curry
spice derived from turmeric. This spice is used as a food preser-
vative and herbal medicine in India (Kelloff et al., 1991; Kelloff et
al., 2000), where the prevalence of AD in patients between 70 and
79 years of age is 4.4-fold less than that of the United States
(Ganguli et al., 2000). Curcumin is several times more potent
than vitamin E as a free radical scavenger (Zhao et al., 1989),
protects the brain from lipid peroxidation (Martin-Aragon et al.,
1997), and scavenges NO-based radicals (Sreejayan and Rao,
1997). Based on these considerations, we tested curcumin for its
ability to inhibit the combined inﬂammatory and oxidative dam-
age that occur as a response to amyloid in the transgenic mouse
model APPSw. This model, which carries a human familial AD
gene (amyloid precursor protein with the “Swedish” double mu-
tation) (Hsiao et al., 1996), displays age-related neuritic plaque
pathology, a quantiﬁable inﬂammatory response (Frautschy et al.,
1998), oxidative damage (Perry and Smith, 1997; Pappolla et al.,
1998; Smith et al., 1998), and age-related memory deﬁcits linked
to defective long-term potentiation (LTP) (Chapman et al., 1999).
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Animals. Ten-month-old male and female APPSw Tg and Tg mice
from 12 litters were randomly split between treatment groups. Tg mice
were fed either chow (PMI Feeds Inc., St. Louis, MO) containing a low
dose of curcumin (160 ppm; n  9; Sigma, St. Louis, MO), a high dose
of curcumin (5000 ppm; n  6), or no drug (n  8) for 6 months before
being killed. Tg littermates were fed chow containing no drug (n  5).
At the time of death, neither the weights nor the ages of the mice were
signiﬁcantly different, and there were no indications of diet-related tox-
icities. Mice were perfused with 0.9% normal saline, followed by HEPES
buffer, pH 7.2, containing 5 mg/ml each leupeptin and aprotinin and 2
mg/ml pepstatin A. Brain regions were dissected from one hemisphere
using mouse brain atlas coordinates (Franklin and Paxinos, 1997) as
reported previously (Lim et al., 2000). Thalamic, cortical, and hippocam-
pal regions, as well as entorhinal cortex and piriform cortex–amygdala
sections, were dissected out and snap frozen in liquid nitrogen. Biochem-
ical measurements were performed in the hippocampus, entorhinal cor-
tex, piriform cortex–amygdala, and residual cortex (cortex region without
frontal, entorhinal, or piriform areas).
Tissue preparation. Tissue samples were processed as described previ-
ously (Lim et al., 2000). Brieﬂy, samples were homogenized in 10 vol of
TBS containing a cocktail of protease inhibitors (20 g/ml each pepstatin
A, aprotinin, phosphoramidon, and leupeptin, 0.5 mM PMSF, and 1 mM
EGTA). Samples were sonicated brieﬂy (two times for 10 sec) and
centrifuged at 100,000  g for 20 min at 4°C. The soluble fraction
(supernatant) was used for interleukin-1 (IL-1) or soluble A
ELISAs, whereas the TBS-insoluble pellet was sonicated in 10 vol of 2%
SDS. The resulting homogenate was centrifuged at 100,000  g for 20
m i na t2 0 °C. The SDS-soluble fraction was used for Western analysis of
GFAP and APP but not for A ELISA. To analyze insoluble A, the
SDS-insoluble pellet was solubilized and sonicated in 70% formic acid.
The resulting extract was neutralized with 0.25 M Tris containing 30%
acetonitrile and 5 M NaOH.
Sandwich ELISA for A. Our sandwich ELISA for total A has been
described previously (Lim et al., 2000). Brieﬂy, the assay uses monoclonal
4G8 against A17–24 (Senentek, Napa, CA) as the capture antibody (3
g/ml), biotinylated 10G4 against A1–15 as the detecting antibody, and
a reporter system using streptavidin–alkaline phosphatase and AttoPhos
(JBL Scientiﬁc Inc., San Luis Obispo, CA) as the substrate (excitation,
450 nm; emission, 580 nm).
Sandwich ELISA for IL-1. This assay using polyclonal antibody
against mouse IL-1 (Endogen, Woburn, MA) for capture and mono-
clonal anti-mouse IL1- (Endogen) for detection can measure IL- down
to 0.5 pg under most conditions (Lim et al., 2000).
Measurement of oxidized proteins. Amounts of oxidized proteins con-
taining carbonyl groups were measured using an Oxyblot kit (Intergen,
Purchase, NY). Brieﬂy, 10 g of protein from the SDS extract were
reacted with 1 dinitrophenylhydrazine (DNPH) for 15–30 min, fol-
lowed by neutralization with a solution containing glycerol and
-mercaptoethanol. These samples were electrophoresed on a 10% Tris–
glycine gel, transferred, and blocked. The blot was incubated overnight
with a rabbit anti-DNPH antibody (1:150) at 4°C, followed by incubation
in goat anti-rabbit (1:300) for 1 hr at room temperature. Bands were
visualized using chemiluminescent techniques with nonsaturating expo-
sures and quantiﬁed.
Immunoblots for GFAP and APP. Levels of GFAP and APP (rabbit
polyclonal 681–695; Kang sequence) were determined on immunoblots
containing 40 g of SDS-soluble brain homogenate. Blots were per-
formed as described previously (Lim et al., 2000).
Immunostaining and image analysis. Immunohistochemistry and image
analysis of anti-amyloid-stained deposits and microglia was performed on
coronal brain sections from Tg untreated and Tg animals treated with
low-dose curcumin as described previously (Lim et al., 2000). Tissue
from the high-dose curcumin (HD curcumin) group was taken for elec-
trophysiology and not available. Brieﬂy, 10 m hemibrain cryostat sec-
tions cut from the posterior pole to the anterior margin of the hippocam-
pus were incubated overnight at 4°C (1:100) in “DAE” polyclonal
antibody (anti-A1–13) made against synthetic peptides A1–13 or an-
tibody against phosphotyrosine (PT), which serves as a rodent microglia
marker (Frautschy et al., 1998). Brieﬂy, antigen retrieval was accom-
plished by incubating sections in an unmasking solution (Vector Labo-
ratories, Burlingame, CA) for 30 sec in a pressure cooker. Sections were
allowed to cool down to room temperature before they were washed with
TBS, and endogenous peroxidase was quenched with 0.3% hydrogen
peroxide for 15 min. After blocking with normal serum, sections were
incubated with anti-PT (1:400) at 37°C for 40 min. Slides were incubated
in biotinylated goat anti-rabbit antibodies for DAE staining (1:1000) or
biotinylated goat anti-mouse antibodies for PT staining (1:1000), fol-
lowed by ABC reagent, each for 30 min at 37°C. Sections were developed
with metal enhanced DAB (Pierce, Rockford, IL). On adjacent sections,
DAE yielded similar results to monoclonal antibodies A17–24 (4G8) or
A37–42 (2G9, 7A3). However, the rabbit polyclonal DAE was used for
image analysis because it lacked the occasional vascular artifacts present
when mouse monoclonals are used on mouse tissue.
Image analysis of DAE was performed on two coronal sections per
brain. All images were acquired from an Olympus Optical (Tokyo,
Japan) Vanox-T microscope with an Optronix Engineering LX-450A
CCD video system. The video signal was routed into a Macintosh
computer via a Scion Corp. (Frederick, MD) AG-5 averaging frame
grabber, and these digitized images were analyzed with NIH Image
public domain software. Custom Pascal macro subroutines were written
to calculate various parameters of A immunostaining, which included
number of plaques, mean diameter, mean area, mean percentage area,
and total area of plaques. Plaque burden was deﬁned as percentage of
total hippocampal and cortical area stained for A, excluding identiﬁable
vascular labeling. Individual plaque areas were assessed at 20 optical
magniﬁcation, an analysis requiring acquisition of several microscopic
ﬁelds. Total brain region areas were determined with 1 magniﬁcation.
Then plaque areas per hemibrain section were totaled, and this sum area
was divided by total hippocampal and cortical area of the relevant
hemibrain section.
Image analysis was also used to obtain percentage of PT (DAB-
labeled) area in rings of one and two plaque radii around anti-A–vector
blue-labeled plaques and in cortical and hippocampal neuronal layers
(layers 1–6 of parietal, occipital, and temporal cortex; layers 1–3o f
entorhinal cortex and hippocampal stratum oriens and lacunosum, outer
and inner molecular layers, and hilus of the dentate).
Statistical analyses. A two-factor ANOVA (treatment  region or
transgene  region) was performed to analyze differences in levels of
IL-1, GFAP, soluble and insoluble A, carbonyl proteins (Oxyblot),
and image analysis data. For evaluating microglial response to plaques in
the ring analysis, a 2  2 ANOVA of microglial staining (percentage
area) was performed, with treatment and ring being analyzed. Ring 1
labeling measures microglial staining within plaques, whereas ring 2
labeling measures microglial staining in the immediate vicinity but out-
side of plaques. A “ring effect” would signify that microglial staining is
dependent on proximity to plaques. A treatment by ring interaction
would imply that treatment effect may be dependent on ring. Post hoc
comparisons between regions were performed using Fisher’s PLSD.
Bartlett’s test for homogeneity of variances was also performed to de-
termine whether variances were equal. Some analyses required logarith-
mic or square root transformations to establish homogeneity. p  0.05
was considered signiﬁcant.
RESULTS
Curcumin decreases IL-1 levels in Tg mice
Accumulating evidence implicates interleukin-1 in AD pathogen-
esis (Sheng et al., 1996; Grifﬁn et al., 1998, 2000). We chose to
assay interleukin-1 because it is not only involved in AD and
elevated in Tg2576 (Lim et al., 2000) but also because age-related
elevations of IL-1 in rodents have been implicated in age-related
memory loss and defective LTP (Murray and Lynch, 1998). Lev-
els of IL-1 were measured from the soluble fraction of three diet
groups: Tg untreated, Tg low-dose curcumin, and Tg HD
curcumin. Measurements were made in four brain regions (hip-
pocampus, entorhinal cortex, piriform cortex, and residual cortex)
and analyzed by two-factor ANOVA (diet  region). Our previ-
ous studies revealed a signiﬁcant transgene effect in Tg mice
compared with Tg mice, in which IL-1 levels were elevated
2.4–6.7-fold in various regions of the brain (Lim et al., 2000). In
the current study, two-way ANOVA showed a signiﬁcant treat-
ment effect with low-dose curcumin, decreasing IL-1 expression
by 61.8% (F(1,57)  19.6; p  0.0001) (Fig. 1A), with a signiﬁcant
treatment–region interaction. In addition, high doses of curcumin
also signiﬁcantly lowered IL-1 levels in Tg mice by 57%
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high doses of curcumin can decrease levels of IL-1 in Tg mice.
Immunoblot analysis was used to determine whether curcumin
could lower levels of GFAP, an astrocyte marker that is often
elevated in inﬂammatory conditions and is increased in amyloid-
forming APP transgenic mice (Irizarry et al., 1997). Levels of
GFAP were signiﬁcantly increased by 20% in APPSw mice (Lim
et al., 2000). Two-way ANOVA demonstrated a signiﬁcant treat-
ment effect with low-dose curcumin, in which levels were de-
creased by 16.5% (F(1,58)  4.8; p  0.03). No signiﬁcant treat-
ment effects were observed with high-dose curcumin (data not
shown).
Microglial activation was estimated by measuring the percent-
age of PT-stained area on cryostat sections in untreated and
curcumin-treated (low-dose) animals. Two-way ANOVA (diet 
region) demonstrated a diet effect in cortical and hippocampal
layers in treated animals, in which percentage of PT-stained area
was signiﬁcantly reduced by 31% ( p  0.0001) (Fig. 2A,B).
Curcumin had the greatest impact on the outer molecular layer of
the hippocampus and layer two of the cortex (data not shown). As
shown in Figure 2, C and D, curcumin did not signiﬁcantly reduce
microglial staining within plaques (ring 1) and even signiﬁcantly
increased plaque-associated PT immunolabeling immediately
outside of plaques (ring 2).
Oxidative damage is reduced in curcumin-treated mice
Oxidative damage was assessed in Tg untreated, Tg un-
treated, and Tg HD curcumin groups using Western blot anal-
ysis, in which carbonyl groups on oxidized proteins were deriv-
itized with DNPH and detected using an anti-DNP antibody. A
representative example of an Oxyblot is shown in Figure 3.
Two-way ANOVA (transgene  region) revealed a signiﬁcant
transgene effect in oxidized protein levels, which were increased
10.7-fold in Tg untreated mice (F(1,36)  47.6; p  0.0001) (Fig.
3B), consistent with previous reports of oxidative damage in
APPSw mice. A combined regional analysis of all four brain
regions revealed that animals treated with high doses of curcumin
had a signiﬁcantly lower level of oxidized proteins (46.3%) com-
pared with untreated animals (F(1,47)  6.3; p  0.01) (Fig. 3C).
Oxidative damage was measured in two brain regions (residual
cortex and piriform cortex) of animals treated with the low dose
of curcumin. Two-way ANOVA revealed a signiﬁcant treatment
effect with low-dose curcumin, in which oxidized protein levels
were reduced 61.5% in treated animals (F(1,31)  7.31; p  0.01)
(Fig. 3D). Therefore, both low and high doses of curcumin sig-
niﬁcantly decreased levels of oxidized proteins in the APPSw
mice.
Low doses of curcumin reduce TBS-soluble A and
SDS-insoluble A (amyloid)
Previous studies have shown that a chronic dose of ibuprofen
signiﬁcantly reduces insoluble and soluble A in APPSw mice
(Lim et al., 2000). We tested whether this same effect was seen in
curcumin-treated animals. Levels of SDS-insoluble A were mea-
sured by ELISA in entorhinal cortex, hippocampus, and residual
cortex regions. Two-way ANOVA (treatment  region) revealed
a signiﬁcant reduction in insoluble A (F(1,36)  10.97; p 
0.002), in which amounts were lowered by 39.2% (Fig. 4A). There
was also a signiﬁcant region-dependent effect (F(2,36)  13.7; p 
0.0001), in which insoluble A levels were decreased in all regions
except in residual cortex (data not shown). High doses of cur-
cumin, on the other hand, did not alter the level of insoluble A
in the brains of treated mice (data not shown).
Two-way ANOVA (treatment  region) revealed a signiﬁcant
reduction in the level of soluble A in animals treated with low-
dose curcumin (F(1,61)  4.02; p  0.0492), in which amounts were
decreased by 43% (Fig. 4C). Soluble A levels were unchanged
with high-dose curcumin treatment (F(1,48)  0.192; p  0.66).
Low doses of curcumin reduces plaque burden in
APPSw brains
To evaluate whether curcumin treatment affected plaque pathol-
ogy, cryostat hemibrain sections from Tg control and Tg
low-dose curcumin-treated mice were immunostained with an
antibody against A1–13 (DAE). Two-factor ANOVA (treat-
ment  region) revealed a signiﬁcant reduction in plaque burden
in curcumin-treated animals (F(1,60)  4.74; p  0.03), in which
amyloid burden was decreased by 43.6% in treated animals com-
pared with untreated animals (Fig. 4B). Additional analysis of the
data showed that total area of plaques was also decreased by
42.7% in curcumin-treated animals (with square root transforma-
tion to achieve the homogeneity of variance required for
ANOVA; p  0.01). The mean number of plaques was reduced
32.6% (log transformation for homogeneity of variance; p 
0.045). Although there was a mean 14% decrease in the size of
the plaque with curcumin treatment, this observation was not
statistically signiﬁcant ( p  0.33). The mean diameter of the
plaque was also not statistically reduced ( p  0.70).
DISCUSSION
In this study, we report that the Indian spice curcumin suppresses
indices of inﬂammation and oxidative damage in the brains of
APPSw mice, factors that have been implicated in AD pathogen-
esis. Furthermore, low, nontoxic doses of curcumin decrease
levels of insoluble and soluble amyloid and plaque burden in
many affected brain regions.
Curcumin is a potent anti-inﬂammatory compound. Part of its
NSAID-like activity is based on the inhibition of nuclear factor
B( N F B)-mediated transcription of inﬂammatory cytokines
(Xu et al., 1998), inducible nitric oxide synthase (iNOS) (Chan et
al., 1998), and cyclooxygenase 2 (Zhang et al., 1999). Elevated
IL-1 has been linked to neuroinﬂammatory cascades involved in
neuritic plaque pathogenesis (Sheng et al., 1996; Grifﬁn et al.,
Figure 1. Effect of curcumin on IL-1 on APPSw brains. A, Effect of
low-dose curcumin on IL-1. Protein levels were measured in TBS-
extracted supernatant from Tg mice fed low-dose curcumin diet and
untreated Tg mice. Levels of IL-1 were signiﬁcantly decreased by
61.8%. in curcumin-treated animals. *p  0.05. B, Effect of high-dose
curcumin on IL-1. Protein levels were measured in TBS-extracted su-
pernatant from Tg mice fed a high-dose curcumin diet and untreated
Tg mice. Two-way ANOVA revealed a 57% reduction in IL-1 levels in
Tg mice receiving a high dose of curcumin compared with untreated
animals. ***p  0.001.
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Both low and high doses of curcumin were effective in signiﬁ-
cantly lowering our principal index of inﬂammation, the proin-
ﬂammatory cytokine IL-1 by 57–61.8%, suggesting that inﬂam-
mation was reduced in curcumin-treated animals. GFAP, an
astrocytic marker associated with injury and inﬂammatory pro-
cesses, was also signiﬁcantly reduced with low-dose curcumin
treatment. Similarly, another index of inﬂammation, PT immu-
nolabeling of microglia in cortical and hippocampal neuronal
layers, was signiﬁcantly reduced by curcumin treatment.
Extensive evidence of oxidative damage has been reported in
AD (Conrad et al., 2000; Pratico ` and Delanty, 2000; Varadarajan
et al., 2000) and results in lipid peroxidation products such as
4-hydroxynonenal and isoprostanes (Montine et al., 1998; Pratico `
et al., 1998). Immunohistochemical evidence of peri-plaque oxi-
dative damage has been found in aged APPSw mice (Perry and
Smith, 1997; Pappolla et al., 1998; Smith et al., 1998). In Tg
animals, we detected markedly elevated protein carbonyl forma-
tion using a convenient quantiﬁable Western blot analysis of
DNPH derivatized carbonyls. Low and high doses of curcumin
clearly suppressed the level of elevated protein carbonyls by
46–61.5%, which is consistent with its known antioxidant activity
in brain (Rajakumar and Rao, 1994; Sreejayan and Rao, 1994;
Kaul and Krishnakantha, 1997). Oxidized protein levels were not
Figure 2. Reductions in percentage of stained microglia in response to dietary curcumin (160 ppm) were observed in neuronal layers in every region
examined except the hilus of the hippocampus (A). Layers 1 of the cortex and the stratum oriens of the hippocampus were minimally affected, whereas
the most robust reductions were observed in layer 2 of the cortex (40% reduction) and the outer molecular layer (OML) of the dentate gyrus (53%
reduction). An example of the PT staining quantiﬁed in the OML is shown in B. D, Percentage of PT staining was quantiﬁed within plaques (ring 1) and
associated within 1 plaque radius (ring 2). Whether curcumin altered the association of microglia with plaques was analyzed by analysis of the staining
within these rings, using a 2  2 ANOVA (treatment diet  ring) of microglial staining (percentage area). A ring effect signiﬁes that microglial staining
is dependent on proximity to the plaque. The treatment  ring interaction signiﬁes that curcumin treatment effects depend on the ring analyzed. As
shown in C, microglial PT staining was not reduced within plaques (ring 1) but was even increased in ring 2 around plaques in curcumin-treated animals.
IML, Inner molecular layer.
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Because ibuprofen reduces inﬂammation indexed by IL-1 and
plaque-associated microgliosis, this result suggests that reactive
oxygen species (ROS) secondary to inﬂammation in plaque-
associated reactive glia (Fig. 5) are not the primary source of
increased ROS-driven oxidative damage in this -amyloidosis
model. This conclusion is consistent with a recent report in which
isoprostanes were elevated in young mice before plaque forma-
tion and associated reactive glia (Pratico ` et al., 2001). These
results suggest a combined antioxidant and NSAID approach to
AD prevention or therapeutics.
Studies indicate that there is a reduced age-adjusted prevalence
of AD in India (Ganguli et al., 2000), as well as a lower prevalence
of Parkinson’s disease (Muthane et al., 1998). Both diseases are
linked to increased oxidative damage, including NO-based dam-
age to a speciﬁc protein, synuclein (Glasson et al., 2000). Cur-
cumin may effectively inhibit this damage.
Low-dose curcumin treatment signiﬁcantly lowered both over-
all insoluble amyloid and plaque burden by 39 and 43%, respec-
tively. These A-lowering effects were not mediated by reduc-
tions in APP expression because we did not see any decrease in
APP production in the SDS fraction of curcumin-treated mice
Figure 3. Measurement of oxidized pro-
teins in APPSw mice. A, Representative
example of Oxyblot using 10 g of protein
from Tg untreated and Tg untreated
entorhinal cortex samples. B, Transgene ef-
fect on oxidized proteins, as measured by
Oxyblot, of SDS-extracted supernatant
from hippocampus and entorhinal cortex of
Tg untreated (n  9) and Tg untreated
(n  6). Two-way ANOVA showed a highly
signiﬁcant transgene effect, in which the lev-
els of oxidized proteins were 12-fold higher
in Tg animals compared with Tg ani-
mals. ***p  0.001. C, High-dose curcumin
effect. Levels of oxidized proteins in oxy-
blots of SDS-extracted supernatant from
hippocampal, entorhinal, and piriform cor-
tices of Tg untreated (n  6) and Tg
high-dose curcumin (n  8). Two-way
ANOVA showed that levels of oxidized
proteins were 46% lower in mice fed a diet
containing a high-dose of curcumin (HD
curcumin). *p  0.05. D, Low-dose cur-
cumin effect. Amounts of oxidized proteins
in residual cortex and piriform cortex of
Tg untreated and Tg curcumin-treated
animals. Two-way ANOVA revealed a sig-
niﬁcant treatment effect. *p  0.05. OD,
Optical density.
Figure 4. Effect of low-dose curcumin on SDS-
insoluble A and plaque pathology. A, Formic
acid extracted (SDS-insoluble) A as measured
by sandwich ELISA. A was measured in the
three regions of the brain: hippocampus, ento-
rhinal cortices, and residual cortex. A two-way
ANOVA (treatment  region) showed signiﬁ-
cant treatment effects in insoluble A levels
(***p  0.001). Homogeneity of variance was
obtained using a natural log transformation of
square root transformed values. B, Plaque bur-
den (percentage of hippocampal and cortical
area stained with amyloid) in Tg untreated and
Tg low-dose curcumin mice. Image analysis
was performed on amyloid-positive structures
(DAE-positive) in hemibrain cryostat sections. Two-way ANOVA revealed a signiﬁcant 43% reduction in plaque burden in curcumin-treated animals
(*p  0.03). C, Soluble A in Tg untreated and Tg low-dose curcumin mice as measured by sandwich ELISA. A levels were measured in
hippocampus, entorhinal cortex, piriform cortex, and residual cortex regions. Two-way ANOVA (treatment - region) showed signiﬁcant treatment effects
in decreasing the levels of soluble A (*p  0.05).
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(Cole et al., 1992) (data not shown). Although we did not see any
consistent effect on APP levels, additional experiments are re-
quired to determine whether curcumin inﬂuences APP process-
ing. These ﬁndings are consistent with previous observations seen
in ibuprofen-treated animals (10–16 months old), in which amy-
loid levels and plaque pathology were decreased by 50% (Lim et
al., 2000). High-dose curcumin treatment, however, did not affect
the amount of insoluble amyloid. Soluble A levels were also
signiﬁcantly lowered by 43% in animals treated with low doses of
curcumin, which is consistent with previous observations seen in
mice treated with ibuprofen (Lim et al., 2000). Because “soluble
A” fractions may be involved with neurotoxicity, our data sug-
gest that NSAIDs such as curcumin and ibuprofen can protect
against neurotoxicity by reducing the level of these fractions.
Potential mechanisms underlying these curcumin treatment
effects are multifactorial, as illustrated in a schematic diagram
(Fig. 5). Curcumin suppressed microgliosis in neuronal layers but
failed to reduce microgliosis within plaques and even signiﬁcantly
increased microgliosis immediately adjacent to plaques, raising
the possibility that it may stimulate microglial phagocytosis of
amyloid. Other possible mechanisms include inhibition of IL-1-
induced increases in alpha-1-antichymotrypsin (1ACT) and
NFB-mediated transcription of apolipoprotein E (ApoE). Both
1ACT (Rozemuller et al., 1990; Shoji et al., 1991; Aksenova et
al., 1996) and ApoE (Wisniewski and Frangione, 1992;
Wisniewski et al., 1994; Weisgraber and Mahley, 1996; Beffert et
al., 1999) have been shown to be proamyloidogenic in APP
transgenic mice. Curcumin can reduce two other proamyloido-
genic pathways: oxidative damage (Bush et al., 1994; Friedlich
and Butcher, 1994; Hensley et al., 1994) and cholesterol levels
(Soudamini et al., 1992; Ramirez-Tortosa et al., 1999; Kamal-
Eldin et al., 2000). Cholesterol could promote amyloidogenesis by
regulating - and -secretase activity (Bodovitz and Klein, 1996;
Frears et al., 1999; Wolozin, 2001).
In addition to the illustrated inﬂammation-related targets, cur-
cumin is also reported to inhibit lipoxygenases and phospholipase
D (Yamamoto et al., 1997; Began and Sudharshan, 1998;
Skrzypczak-Jankun et al., 2000), which could contribute to over-
all NSAID or neuroprotective function. Given that there are
multiple curcumin targets with varying dose–response curves, it is
not surprising that some effects are dose related. For example, the
amyloid reduction effect was dose-dependent and lost at 5000
ppm. One explanation for this effect may be that high doses of
curcumin appear to suppress glial amyloid clearance in organo-
typic hippocampal slice cultures (T. Chu, G. P. Lim, and G. M.
Cole, our unpublished observations), which could counterbalance
any anti-amyloidogenic effects. Ongoing efforts at dissection of
the relative importance of the different possible pathways for the
amyloid reduction effects by curcumin may or may not reveal a
single essential mode of action. In fact, the ability of curcumin to
partially block multiple pathways implicated in AD pathogenesis
may potentially provide greater in vivo efﬁcacy than more potent
but speciﬁc inhibitors of any of the individual targets.
Curcumin has an extensive history as a food preservative and
medicinal herb in India (Ammon and Wahl, 1991), and it is
possible that widespread curcumin use may contribute to the
reduced age-adjusted prevalence of AD in India (Ganguli et al.,
2000). Studies have consistently shown that curcumin is relatively
nontoxic and has few side effects at doses greater than the low
Figure 5. Curcumin blocks AD pathogene-
sis at multiple sites. Curcumin can act as a
scavenger of ROS, including NO and per-
oxynitrite generated by reactive glia and hy-
droxyl radicals generated by neurons as a
result of direct A toxicity. Ibuprofen
(NSAID action at site 1) can inhibit micro-
glial activation and cytokine production but
was not sufﬁcient to reduce oxidative dam-
age. Antioxidants that can block ROS at
multiple sites may be required. Curcumin
can also limit damage by inhibiting NFB-
induced iNOS, cyclooxygenase 2, and in-
ﬂammatory cytokine production by reactive
glia. By blocking NFkB and reducing IL-1,
IL-6, and ApoE, curcurmin should reduce
proamyloidogenic factors (APOE, 1ACT).
Finally, curcumin can lower plasma and tis-
sue cholesterol, potentially lowering A pro-
duction. LOX, Lipoxygenase; Cox-2, cyclo-
oxygenase 2; SCR, Scavenger receptors; Fc,
Fc Ig receptors.
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studies performed at 2000 mg/kg, which is 83-fold greater than
our low-dose curcumin treatment (24 mg/kg), revealed no mor-
talities in any group of mice tested; the compound also had a low
ulcerogenic index (Srimal and Dhawan, 1972). Even with the
high-dose curcumin treatment (5000 ppm), which is 31-fold
greater than our low dose of curcumin, there was no impact on
presynaptic markers and no increase in GFAP in any region,
consistent with the absence of overt CNS toxicity (data not
shown). Although side effects have been limited in chronic animal
and short-term clinical studies, sustained clinical trials are needed
to establish the safety of chronic curcumin at antioxidant and
anti-inﬂammatory doses.
In summary, at the relatively low, 160 ppm dose, curcumin
signiﬁcantly suppressed the inﬂammatory cytokine IL-1 and the
astrocytic inﬂammatory marker GFAP, reduced oxidative dam-
age, and decreased overall insoluble amyloid, soluble amyloid,
and plaque burden. In a rat intraventricular A infusion model, a
similar dose of dietary curcumin reduced an isoprostane index of
oxidative damage, amyloid plaque burden, and A-induced spa-
tial memory deﬁcits in the Morris water maze (Frautschy et al.,
2001). Hence, curcumin is not only efﬁcacious at multiple levels
but may have fewer side effects and toxicity issues than many
other NSAIDs, including ibuprofen. Together, the multiple ben-
eﬁcial effects of curcumin make it a promising agent for con-
trolled clinical trials to establish its safety and efﬁcacy as a chronic
antioxidant and NSAID prophylactic for prevention or treatment
of Alzheimer’s and possibly other neurodegenerative diseases of
aging, such as Parkinson’s disease.
REFERENCES
Adams JD, Klaidman LK, Odunze IN, Shen HC, Miller CA (1991)
Alzheimer’s and Parkinson’s disease. Brain levels of glutathione, glu-
tathione disulﬁde, and vitamin E. Mol Chem Neuropathol 14:213–226.
Aksenova MV, Aksenov MY, Butterﬁeld DA, Carney JM (1996)
Alpha-1-antichymotrypsin interaction with a beta (1–40) inhibits ﬁbril
formation but does not affect the peptide toxicity. Neurosci Lett
211:45–48.
Ammon HP, Wahl MA (1991) Pharmacology of Curcuma longa. Planta
Med 57:1–7.
Beffert U, Aumont N, Dea D, Lussier-Cacan S, Davignon J, Poirier J
(1999) Apolipoprotein E isoform-speciﬁc reduction of extracellular
amyloid in neuronal cultures. Brain Res Mol Brain Res 68:181–185.
Began G, Sudharshan E, Appu Rao AG (1998) Inhibition of lipoxygen-
ase 1 by phosphatidylcholine micelles-bound curcumin. Lipids
33:1223–1228.
Behl C, Davis JB, Lesley R, Schubert D (1994) Hydrogen peroxide
mediates amyloid  protein toxicity. Cell 77:817–827.
Bjorkman D (1998) Nonsteroidal anti-inﬂammatory drug-associated tox-
icity of the liver, lower gastrointestinal tract, and esophagus. Am J Med
105:17S–21S.
Bodovitz S, Klein WL (1996) Cholesterol modulates alpha-secretase
cleavage of amyloid precursor protein. J Biol Chem 271:4436–4440.
Breitner JCS, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD,
Pericak-Vance MA, Saunders AM (1995) Delayed onset of Alzhei-
mer’s disease with nonsteroidal anti-inﬂammatory and Histamine H2
blocking drugs. Neurobiol Aging 16:523–530.
Bush AI, Pettingell Jr WH, de Paradis M, Tanzi RE, Wasco W (1994)
The amyloid beta-protein precursor and its mammalian homologues.
Evidence for a zinc-modulated heparin-binding superfamily. J Biol
Chem 269:26618–26621.
Cappell MS, Schein JR (2000) Diagnosis and treatment of nonsteroidal
anti-inﬂammatory drug-associated upper gastrointestinal toxicity. Gas-
troenterol Clin North Am 29:97–124.
Chan MM, Huang HI, Fenton MR, Fong D (1998) In vivo inhibition of
nitric oxide synthase gene expression by curcumin, a cancer preventive
natural product with anti-inﬂammatory properties. Biochem Pharmacol
55:1955–1962.
Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ,
Irizarry M, Younkin L, Good MA, Bliss TV, Hyman BT, Hsiao K
(1999) Impaired synaptic plasticity and learning in amyloid precursor
protein transgenic mice. Nat Neurosci 2:271–276.
Christen S, Woodall AA, Shigenaga MK, Southwell-Keely PT, Duncan
MW, Ames BN (1997) Gamma-tocopherol traps mutagenic electro-
philes such as NOx and complements alpha-tocopherol: physiological
implications. Proc Natl Acad Sci USA 94:3217–3222.
Cole GM, Bell L, Truong QB, Saitoh T (1992) An endosomal lysosomal
pathway for degradation of amyloid precursor protein. Ann NY Acad
Sci 674:103–117.
Conrad CC, Marshall PL, Talent JM, Malakowsky CA, Choi J, Gracy RW
(2000) Oxidized proteins in Alzheimer’s plasma. Biochem Biophys
Res Commun 275:678–681.
Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxis coor-
dinates, Ed 1. London: Academic.
Frautschy SA, Yang F, Irrizarry M, Hyman B, Saido TC, Hsiao K, Cole
GM (1998) Microglial response to amyloid plaques in APPsw trans-
genic mice. Am J Pathol 152:307–317.
Frautschy SA, Hu W, Miller SA, Kim P, Harris-White ME, Cole GM
(2001) Phenolic anti-inﬂammatory antioxidant reversal of A-induced
cognitive deﬁcits and neuropathology. Neurobiol Aging, in press.
Frears ER, Stephens DJ, Walters CE, Davies H, Austen BM (1999) The
role of cholesterol in the biosynthesis of beta-amyloid. NeuroReport
10:1699–1705.
Friedlich AL, Butcher LL (1994) Involvement of free oxygen radicals in
-amyloidosis: an hypothesis. Neurobiol Aging 15:443–455.
Ganguli M, Chandra V, Kamboh MI, Johnston JM, Dodge HH, Thelma
BK, Juyal RC, Pandav R, Belle SH, DeKosky ST (2000) Apolipopro-
tein E polymorphism and Alzheimer disease: the Indo-US Cross-
National Dementia Study. Arch Neurol 57:824–830.
Glasson BT, Dude JE, Murray IV, Chen Q, Souza JM, Hurtig HI,
Ischiropoulos H, Trojanowski JQ, Lee VM (2000) Oxidative damage
linked to neurodegeneration by selective alpha-synuclein nitration in
synucleinopathy lesions. Science 290:985–989.
Grifﬁn WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE,
Graham DI, Roberts GW, Mrak RE (1998) Glial-neuronal interac-
tions in Alzheimer’s disease: the potential role of a “cytokine cycle” in
disease progression. Brain Pathol 8:65–72.
Grifﬁn WS, Nicoll JA, Grimaldi LM, Sheng JG, Mrak RE (2000) The
pervasiveness of interleukin-1 in Alzheimer’s pathogenesis: a role for
speciﬁc polymorphisms in disease risk. Exp Gerontol 35:481–487.
Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF,
Floyd RA, Butterﬁeld DA (1994) A model for -amyloid aggregation
and neurotoxicity based on free radical generation by the peptide:
relevance to alzheimer disease. Proc Natl Acad Sci USA 91:3270–3274.
Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang
F, Cole G (1996) Correlative memory deﬁcits, A elevation and amy-
loid plaques in transgenic mice. Science 274:99–102.
Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT (1997)
APPSw transgenic mice develop age-related A beta deposits and neu-
ropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp
Neurol 56:965–973.
Kamal-Eldin A, Frank J, Razdan A, Tengblad S, Basu S, Vessby B (2000)
Effects of dietary phenolic compounds on tocopherol, cholesterol, and
fatty acids in rats. Lipids 35:427–435.
Kaul S, Krishnakantha TP (1997) Inﬂuence of retinol deﬁciency and
curcumin/turmeric feeding on tissue microsomal membrane lipid per-
oxidation and fatty acids in rats. Mol Cell Biochem 175:43–48.
Kelloff GJ, Crowell JA, Hawk ET, Steele VE, Lubet RA, Boone CW,
Covey JM, Doody LA, Omenn GS, Greenwald P, Hong WK, Parkin-
son DR, Bagheri D, Baxter GT, Blunden M, Doeltz MK, Eisenhauer
KM, Johnson K, Knapp GG, Longfellow DG, Malone WF, Nayﬁeld
SG, Seifried HE, Swall LM, Sigman CC (1991) Strategy and planning
for chemopreventive drug development: clinical development plans II.
J Cell Biochem Suppl 26:54–71.
Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW,
Kopelovich L, Hawk ET, Lieberman R, Lawrence JA, Ali I, Viner JL,
Sigman CC (2000) Progress in cancer chemoprevention: development
of diet-derived chemopreventive agents. J Nutr 130:467S–471S.
Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O,
Hsiao Ashe K, Frautschy SA, Cole GM (2000) Ibuprofen suppresses
plaque pathology and inﬂammation in a mouse model for Alzheimer’s
disease. J Neurosci 20:5709–5714.
Lim GP, Yang F, Chu T, Gahtan E, Ubeda O, Beech W, Overmier JB,
Hsiao Ashe K, Frautschy SA, Cole GM (2001) Ibuprofen effects of
Alzheimer pathology and open ﬁeld activity in APPsw transgenic mice.
Neurobiol Aging, in press.
Martin-Aragon S, Benedi JM, Villar AM (1997) Modiﬁcations on anti-
oxidant capacity and lipid peroxidation in mice under fraxetin treat-
ment. J Pharm Pharmacol 49:49–52.
Mattson MP, Goodman Y (1995) Different amyloidogenic peptides
share a similar mechanism of neurotoxicity involving reactive oxygen
species and calcium. Brain Res 676:219–224.
McGettigan P, Henry D (2000) Current problems with non-speciﬁc
COX inhibitors. Curr Pharm Des 6:1693–1724.
Montine TJ, Markesbery WR, Roberts RJI, Morrow JD (1998) Cere-
brospinal ﬂuid F2-isoprostane levels are increased in Alzheimer’sd i s -
ease. Ann Neurol 44:410–413.
Montine TJ, Markesbery WR, Zackert W, Sanchez SC, Roberts LJ,
8376 J. Neurosci., November 1, 2001, 21(21):8370–8377 Lim et al. • Curcumin Reduces Alzheimer Pathology in APP TransgenicsMorrow JD (1999) The magnitude of brain lipid peroxidation corre-
lates with the extent of degeneration but not with density of neuritic
plaques or neuroﬁbrillary tangles or with ApoE genotype in Alzhei-
mer’s disease patients. Am J Pathol 155:863–868.
Murray CA, Lynch MA (1998) Evidence that increased hippocampal
expression of the cytokine interleukin-1 beta is a common trigger for
age- and stress-induced impairments in long-term potentiation. J Neu-
rosci 18:2974–2981.
Muthane U, Yasha TC, Shankar SK (1998) Low numbers and no loss of
melanized nigral neurons with increasing age in normal human brains
from India. Ann Neurol 43:283–287.
Pappolla MA, Chyan Y-J, Omar RA, Hsiao K, Perry G, Smith MA,
Bozner P (1998) Evidence of oxidative stress and in vivo neurotoxicity
of -amyloid in a transgenic mouse model of Alzheimer’s disease. Am J
Pathol 152:871–877.
Perry G, Smith MA (1997) A central role for oxidative damage in the
pathogenesis and therapeutics of Alzheimer’s disease. Alzheimer’s Res
2:319–324.
Pratico ` D, Delanty N (2000) Oxidative injury in diseases of the central
nervous system: focus on Alzheimer’s disease. Am J Med 109:577–585.
Pratico ` D, Lee VM-Y, Trojanowski JQ, Rokach J, FitzGerald GA (1998)
Increased F2-isoprostanes in Alzheimer’s disease: evidence for en-
hanced lipid peroxidation in vivo. FASEB J 12:1777–1783.
Pratico ` D, Uryu K, Leight S, Trojanowski JQ, Lee VM (2001) Increased
lipid peroxidation preces amyloid plaque formation in an animal model
of Alzheimer amyloidosis. J Neurosci 21:4183–4187.
Rajakumar DV, Rao MN (1994) Antioxidant properties of dehydroz-
ingerone and curcumin in rat brain homogenates. Mol Cell Biochem
140:73–79.
Ramirez-Tortosa MC, Mesa MD, Aguilera MC, Quiles JL, Baro L,
Ramirez-Tortosa CL, Martinez-Victoria E, Gil A (1999) Oral admin-
istration of a turmeric extract inhibits LDL oxidation and has hypocho-
lesterolemic effects in rabbits with experimental atherosclerosis. Ath-
erosclerosis 147:371–378.
Rogers J, Webster S, Lih-Fen L, Brachova L, Civin WH, Emmerling M,
Brenda S, Walker D, McGeer P (1996) Inﬂammation and Alzheimer’s
disease pathogenesis. Neurobiol Aging 17:681–686.
Rozemuller JM, Stam FC, Eikelenboom P (1990) Acute phase proteins
are present in amorphous plaques in the cerebral but not in the
cerebellar cortex of patients with Alzheimer’s disease. Neurosci Lett
119:75–78.
Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M,
Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal
LJ (1997) A controlled trial of selegiline, alpha-tocopherol, or both as
treatment for Alzheimer’s disease. The Alzheimer’s disease coopera-
tive study. N Engl J Med 336:1216–1222.
Sheng JG, Ito K, Skinner RD, Mrak RE, Rovnaghi CR, Van Eldik LJ,
Grifﬁn ST (1996) In vivo and in vitro evidence supporting a role for
the inﬂammatory cytokine interleukin-1 as a driving force in Alzhei-
mer pathogenesis. Neurobiol Aging 17:761–766.
Shoji M, Hirai S, Yamaguchi H, Harigaya Y, Ishiguro K, Matsubara E
(1991) Alpha 1-antichymotrypsin is present in diffuse senile plaques. A
comparative study of beta-protein and alpha 1-antichymotrypsin im-
munostaining in the Alzheimer brain. Am J Pathol 138:247–257.
Skrzypczak-Jankun E, McCabe NP, Selman SH, Jankun J (2000) Cur-
cumin inhibits lipoxygenase by binding to its central cavity: theoretical
and X-ray evidence. Int J Mol Med 6:521–526.
Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd
RA, Markesbery WR (1991) Excess brain protein oxidation and en-
zyme dysfunction in normal aging and Alzheimer disease. Proc Natl
Acad Sci USA 88:10540–10543.
Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G (1997)
Widespread peroxynitrite-mediated damage in Alzheimer’s disease.
J Neurosci 17:2653–2657.
Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PLR, Siedlank SL,
Tabaton M, Perry G (1998) Amyloid- deposition is Alzheimer trans-
genic mice is associated with oxidative stress. J Neurochem
70:2212–2215.
Soudamini KK, Unnikrishnan MC, Soni KB, Kuttan R (1992) Inhibition
of lipid peroxidation and cholesterol levels in mice by curcumin. Indian
J Physiol Pharmacol 36:239–243.
Sreejayan N, Rao MN (1994) Curcuminoids as potent inhibitors of lipid
peroxidation. J Pharm Pharmacol 46:1013–1016.
Sreejayan N, Rao MNA (1997) Nitric oxide scavenging by curcuminoids.
J Pharm Pharmacol 49:105–107.
Srimal RC, Dhawan BN (1972) Pharmacology of diferuloyl methane
(curcumin), a non-steroidal anti-inﬂammatory agent. J Pharm Pharma-
col 25:447–452.
Stewart WF, Kawas C, Corrada M, Meter EJ (1997) Risk of Alzheimer’s
disease and duration of NSAID use. Neurology 48:626–632.
Sung J, Russell RI, Nyeomans, Chan FK, Chen S, Fock K, Goh KL,
Kullavanijaya P, Kimura K, Lau C, Louw J, Sollano J, Triadiafalopulos
G, Xiao S, Brooks P (2000) Non-steroidal anti-inﬂammatory drug
toxicity in the upper gastrointestinal tract. J Gastroenterol Hepatol
[Suppl] 15:G58–G68.
Tomoda T, Kurashige T, Hayashi Y, Enzan H (1998) Primary changes in
liver damage by aspirin in rats. Acta Paediatr Jpn 40:593–596.
Varadarajan S, Yatin S, Aksenova M, Butterﬁeld DA (2000) Alzhei-
mer’s amyloid beta-peptide-associated free radical oxidative stress and
neurotoxicity. J Struct Biol 130:184–208.
Weisgraber KH, Mahley RW (1996) Human apolipoprotein E: the Alz-
heimer’s disease connection. FASEB J 10:1485–1494.
Wisniewski T, Frangione B (1992) Apolipoprotein E: a pathological
chaperone protein in patients with cerebral and systemic amyloid.
Neurosci Lett 135:235–238.
Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B (1994)
Acceleration of Alzheimer’s ﬁbril formation by apolipoprotein E in
vitro. Am J Pathol 145:1030–1035.
Wolozin B (2001) A ﬂuid connection: cholesterol and Abeta. Proc Natl
Acad Sci USA 98:5371–5373.
Xu YX, Pindolia KR, Janakiraman N, Chapman RA, Gautam SC (1998)
Curcumin inhibits IL-1 alpha and TNF-alpha induction of AP-1 and
NK-kB DNA-binding activity in bone marrow stromal cells. Hemato-
pathol Mol Hematol 11:49–62.
Yamamoto H, Hanada K, Kawasaki K, Nishijima M (1997) Inhibitory
effect on curcumin on mammalian phospholipase D activity. FEBS Lett
417:196–198.
Zhang F, Altorki NK, Mestre JR, Subbaramaiah K, Dannenberg AJ
(1999) Curcumin inhibits cyclooxygenase-2 transcription in bile acid-
and phorbol ester-treated human gastrointestinal epithelial cells. Car-
cinogenesis 20:445–451.
Zhao BL, Li XJ, He RG, Cheng SJ, Xin WJ (1989) Scavenging effect of
extracts of green tea and natural antioxidants on active oxygen radicals.
Cell Biophys 14:175–185.
Lim et al. • Curcumin Reduces Alzheimer Pathology in APP Transgenics J. Neurosci., November 1, 2001, 21(21):8370–8377 8377